Hemlibra
| Chemical Name | emicizumab |
| Dosage Form | Injection (subcutaneous; 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/mL) |
| Drug Class | Monoclonal antibodies |
| System | Blood |
| Company | Genentech Inc. |
| Approval Year | 2017 |
Indication
- To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.